Cullinan Therapeutics (CGEM) Set to Release Quarterly Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.8435) per share and revenue of $2.00 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.01). On average, analysts expect Cullinan Therapeutics to post ($3.06) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Cullinan Therapeutics Stock Up 5.5%

Shares of NASDAQ:CGEM opened at $15.75 on Wednesday. Cullinan Therapeutics has a 52 week low of $6.73 and a 52 week high of $23.19. The stock has a market capitalization of $1.01 billion, a P/E ratio of -5.08 and a beta of -0.03. The firm has a fifty day simple moving average of $17.65 and a two-hundred day simple moving average of $15.82.

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total value of $172,560.00. Following the sale, the insider owned 158,844 shares of the company’s stock, valued at approximately $3,426,265.08. This represents a 4.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Wedbush upped their target price on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Wall Street Zen lowered Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. BTIG Research boosted their price objective on Cullinan Therapeutics from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Finally, TD Cowen upgraded Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cullinan Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $33.86.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer. The company builds a portfolio of targeted therapies and immune-modulating treatments designed to address significant unmet needs across hematologic malignancies and solid tumors.

Its development programs include investigational antibody-based therapies and other biologic approaches intended to selectively target cancer cells or activate the immune system. Among its programs are CLN-619, an antibody directed at the MICA and MICB proteins, CLN-418, an immune-activating bispecific molecule, and CLN-049, an investigational treatment designed to engage FLT3 and FLT3 ligand in certain blood cancers.